CR2 and neoplasm: This indicated that the primary effector cells of the anti-tumor immune response were proliferative and activated CD20+ B cells, CD21+ DCs, and CD4+ Th cells, rather than CD8+ cytotoxic T cells within tumor-region M-TLSs.